通过GSK-3β抑制来确定潜在的阿尔茨海默病治疗方法:一种分子对接和动态方法
Yasaman Mohammadi1, Reza Emadi2, Arman Maddahi3
1Faculty of Dentistry, Islamic Azad University, Shiraz Branch, Shiraz, Iran.
Computational biology and chemistry
|May 28, 2024
概括
研究人员确定了五种抑制GSK-3β的天然化合物,这是阿尔茨海默病 (AD) 治疗的有希望的目标. 这些化合物显示出开发新的AD治疗的潜力.
科学领域:
- 计算化学和药物发现
- 神经科学和神经退行性疾病
背景情况:
- 糖原合成酶激酶3β (GSK-3β) 是阿尔茨海默病 (AD) 的关键治疗点.
- 鉴定GSK-3β的新型抑制剂对于推进AD治疗策略至关重要.
研究的目的:
- 选天然化合物以检测它们抑制GSK-3β.的潜力.
- 基于1H-英达-3-碳胺 (INDZ) 支架的新型抑制剂的识别.
- 阐明由选定化合物抑制GSK-3β的基础分子机制.
主要方法:
- 药分析和分子对接,从ZINC数据库中识别潜在的配体.
- 增强分子动力学 (EMD) 模拟 (ESMACS) 来评估联结蛋白复合体的稳定性.
- 用Poisson-Boltzmann或一般化的Born表面积 (MMPBSA/GBSA) 进行分子力学,用于结合自由能量的计算.
- 键和聚类分析,以了解结合相互作用.
主要成果:
- 五种化合物 (2a-6a) 与GSK-3β活性部位残留物显著相互作用.
- 这些化合物表现出具有约束力的自由能量值,与参考合物 (OH8) 相当.
- 分子动力学和结合分析证实了蛋白质活性部位内的稳定相互作用.
结论:
- 已识别的基于INDZ的化合物是GSK-3β的强有力的抑制剂.
- 这些发现为设计更有效的GSK-3β抑制剂用于阿尔茨海默病治疗提供了宝贵的见解.
- 计算方法在指导新型治疗剂的发现方面是有效的.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.8K
相关概念视频
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
